Okay, good.
Mr. Herder, you talked about post-marketing research, about needing, once a drug is on the market, a system of surveillance to make sure that the effect you've seen is still there and that the efficacy and safety are still there. I agree that this is particularly in the case of the rare drugs for which you have low sample sizes. If the drug that has been marketed is found unacceptable and your surveillance shows it's not doing its job, are you foreseeing a mechanism whereby these drugs will actually be withdrawn, if something gets on the formulary, and you say this is not on the formulary because it doesn't do what it has promised?